-
公开(公告)号：US20090221509A1
公开(公告)日：2009-09-03
申请号：US10549718
申请日：2004-03-23
申请人： Hans Georg Rammensee , Stefan Stevanovic , Toni Weinschenk , Claudia Lemmel , Jörg Dengjel , Oliver Schoor
发明人： Hans Georg Rammensee , Stefan Stevanovic , Toni Weinschenk , Claudia Lemmel , Jörg Dengjel , Oliver Schoor
IPC分类号： A61K38/10 , A61K35/12 , C12N5/10 , C12N15/63 , G01N33/68 , A61K38/08 , C07K7/08 , C07K7/06 , C07H21/00
CPC分类号： C07K7/06 , A61K38/00 , C07K14/47 , C07K14/4748 , C07K14/78
摘要： The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID-No. 1 to SEQ ID-No. 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.
摘要翻译： 本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID No。 101，其中肽具有结合人类主要组织相容性复合物（MHC）I类分子的能力。 此外，本发明涉及肽和编码肽的核酸用于制备药物以及用于治疗肿瘤疾病和/或腺瘤性疾病的用途。 此外，描述了具有至少一种肽的药物组合物。
-
公开(公告)号：US20100029573A1
公开(公告)日：2010-02-04
申请号：US11596802
申请日：2005-05-24
CPC分类号： C07K14/4748
摘要： The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.
摘要翻译： 本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID NO。 577，该肽能够结合人类主要组织相容性复合物（MHC）I类的分子。本发明还涉及该肽用于制备药物和用于治疗肿瘤疾病的用途 和/或腺瘤性疾病。 此外，描述了包含至少一种肽的药物组合物。
-
公开(公告)号：US08242239B2
公开(公告)日：2012-08-14
申请号：US12544117
申请日：2009-08-19
CPC分类号： C07K14/4748
摘要： The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.
摘要翻译： 本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID NO。 577，该肽能够结合人类主要组织相容性复合物（MHC）I类的分子。本发明还涉及该肽用于制备药物和用于治疗肿瘤疾病的用途 和/或腺瘤性疾病。 此外，描述了包含至少一种肽的药物组合物。
-
公开(公告)号：US08008431B2
公开(公告)日：2011-08-30
申请号：US11596802
申请日：2005-05-24
CPC分类号： C07K14/4748
摘要： The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibilityg complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides.
摘要翻译： 本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID NO。 577，该肽能够结合人类主要组织相容性复合物（MHC）I类的分子。本发明还涉及肽用于制备药物和治疗肿瘤疾病的用途 和/或腺瘤性疾病。 此外，描述了包含至少一种肽的药物组合物。
-
公开(公告)号：US20100021441A1
公开(公告)日：2010-01-28
申请号：US12544117
申请日：2009-08-19
CPC分类号： C07K14/4748
摘要： The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the pepti
摘要翻译： 本发明涉及具有选自SEQ ID NO：1的氨基酸序列的肿瘤相关肽。 1至SEQ ID NO。 577，该肽能够结合人类主要组织相容性复合物（MHC）I类的分子。本发明还涉及该肽用于制备药物和用于治疗肿瘤疾病的用途 和/或腺瘤性疾病。 此外，描述了包含至少一个该肽的药物组合物
-
公开(公告)号：US20110070253A1
公开(公告)日：2011-03-24
申请号：US12915930
申请日：2010-10-29
申请人： Hans Georg RAMMENSEE , Stefan Stevanovic , Toni Weinschenk , Claudia Trautwein , Jörn Dengjel , Oliver Schoor
发明人： Hans Georg RAMMENSEE , Stefan Stevanovic , Toni Weinschenk , Claudia Trautwein , Jörn Dengjel , Oliver Schoor
IPC分类号： A61K38/10 , C07K7/06 , C07K7/08 , A61K38/08 , A61P35/00 , A61K39/00 , C07K16/00 , A61K38/00 , C07H21/04 , A61K31/7088 , C12N15/63 , C12N5/078 , C12N5/0783 , C12N5/10 , G01N33/53
CPC分类号： C07K7/06 , A61K38/00 , C07K14/47 , C07K14/4748 , C07K14/78
摘要： The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.
摘要翻译： 本发明涉及具有选自所附序列方案的SEQ ID NO：1至SEQ ID NO：101的氨基酸序列的肿瘤相关肽，其中所述肽具有结合分子的能力 的人类主要组织相容性复合体（MHC）I类。 此外，本发明涉及肽和编码肽的核酸用于制备药物以及用于治疗肿瘤疾病和/或腺瘤性疾病的用途。 此外，描述了具有至少一种肽的药物组合物。
-
公开(公告)号：US08647629B2
公开(公告)日：2014-02-11
申请号：US12466222
申请日：2009-05-14
申请人： Hans-Georg Rammensee , Stefan Stevanovic , Cécile Gouttefanges , Toni Weinschenk , Peter Lewandrowski
发明人： Hans-Georg Rammensee , Stefan Stevanovic , Cécile Gouttefanges , Toni Weinschenk , Peter Lewandrowski
CPC分类号： A61K38/10 , A61K39/0011 , C07H21/00 , C07K7/08 , C07K14/4747 , C07K14/4748 , C07K14/7056 , C07K16/18 , C12N15/10 , C12N15/86
摘要： The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译： 本发明涉及用于癌症免疫治疗的肽，核酸和细胞。 本发明还涉及存活蛋白衍生的肿瘤相关细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明具体涉及可衍生自人类肿瘤细胞的HLA I类和II类分子的三种新型肽序列及其变体，其可用于引发抗肿瘤免疫应答的疫苗组合物。
-
8.发明授权HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof 有权衍生自前列腺相关抗原分子的HLA结合肽及其使用方法公开(公告)号：US09023802B2
公开(公告)日：2015-05-05
申请号：US12967606
申请日：2010-12-14
申请人： Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas , Toni Weinschenk , Peter Lewandrowski
发明人： Hans Georg Rammensee , Stefan Stevanovic , Cecile Gouttefangeas , Toni Weinschenk , Peter Lewandrowski
CPC分类号： C07K14/4748 , A61K39/0011 , A61K2039/55566
摘要： Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
摘要翻译： 公开了用于前列腺癌免疫治疗的方法和组合物。 用包含或不含免疫佐剂的来自前列腺相关抗原分子的HLA结合肽的组合物治疗患者。
-
公开(公告)号：US08536304B2
公开(公告)日：2013-09-17
申请号：US12632541
申请日：2010-01-22
IPC分类号： C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
摘要翻译： 本发明涉及含有氨基酸序列的肿瘤相关肽，其选自所附列举的SEQ ID NO：1至SEQ ID NO：79。 该肽具有结合人类主要组织相容性复合体（MHC）I类分子的能力。 本发明还涉及肽用于制备药物和治疗肿瘤疾病的用途。 本发明还涉及包含至少一种肽的药物组合物。
-
公开(公告)号：US08399613B2
公开(公告)日：2013-03-19
申请号：US12632463
申请日：2010-01-22
IPC分类号： C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.031 秒)
